Good research practices for measuring drug costs in cost effectiveness analyses: An industry perspective: The ISPOR drug cost task force report - Part v

Value in Health

Volumn 13, Issue 1, 2010, Pages 25-27

  Mycka, Jack M ^a   Dellamano, Renato ^b   Kolassa, Eugene Mick ^a   Wonder, Michael ^c   Ghosh, Sabyasachi ^d   Hay, Joel W ^e   Smeeding, Jim ^f  

^a MME LLC   (United States)

^b ValueVector Srl   (Italy)

^c Novartis Pharmaceuticals Australia   (Australia)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f JestaRx Group   (United States)

Author keywords

Cost study; Drug cost; Industry; Pharmacoeconomic

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; GOOD MANUFACTURING PRACTICE; MEDICAL PRACTICE; MEDICAL RESEARCH; PRIORITY JOURNAL; SHORT SURVEY;

EID: 72949086642     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00664.x     Document Type: Article

References (0)